SCHEMBL6203632

SCHEMBL6203632

O=C(Nc1cccc(-c2cn3ccnc3c(NCc3ccccc3)n2)c1)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 19/20 0.73
BTK Q06187 2/20 0.67
ABL1 P00519 1/20 0.64
EGFR P00533 1/20 0.64
PRKCB P05771 1/20 0.64
INSR P06213 1/20 0.64
LCK P06239 1/20 0.64
FYN P06241 1/20 0.64
LYN P07948 1/20 0.64
PDGFRB P09619 1/20 0.64
SRC P12931 1/20 0.64
PRKCA P17252 1/20 0.64
FLT1 P17948 1/20 0.64
FGFR4 P22455 1/20 0.64
EPHA2 P29317 1/20 0.64
AKT1 P31749 1/20 0.64
FLT4 P35916 1/20 0.64
KDR P35968 1/20 0.64
FLT3 P36888 1/20 0.64
ZAP70 P43403 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6202976 0.91 EPHB4 (0.84) EPHB4BTKABL1EGFRPRKCB
SCHEMBL4811120 0.87 SYK (0.79) EPHB4BTKABL1EGFRPRKCB
SCHEMBL4806254 0.83 SYK (0.85) EPHB4BTKSYK
SCHEMBL4803219 0.82 BTK (0.85) EPHB4BTKSYK
SCHEMBL6204144 0.82 EPHB4 (0.92) EPHB4
SCHEMBL6220156 0.81 EPHB4 (0.73) EPHB4BTKABL1EGFRPRKCB
SCHEMBL5477799 0.81 BTK (0.61) EPHB4BTKSYK
SCHEMBL5486801 0.80 EPHB4 (1.00) EPHB4BTKABL1EGFRPRKCB
SCHEMBL5486306 0.80 EPHB4 (1.00) EPHB4BTKABL1EGFRPRKCB
SCHEMBL5478193 0.80 EPHB4 (0.67) EPHB4BTKKDRSYKTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100537571-C Imidazo[1,2-a]pyrazin-8-ylamines, method of making and method of use thereof CELLULAR GENOMICS INC (US) 2009-09-09 CN disclosed
US-20050288295-A1 Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. 2005-12-29 US disclosed
CN-1668619-A Imidazo [1, 2-a ] pyrazin-8-ylamines, methods of making and methods of use thereof CELLULAR GENOMICS INC (US) 2005-09-14 CN disclosed
US-6919340-B2 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof CELLULAR GENOMICS, INC. (US) 2005-07-19 US disclosed
EP-1509526-A2 IMIDAZO(1,2-A)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF Cellular Genomics Inc. (US) 2005-03-02 EP disclosed
US-20030212073-A1 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof GILEAD CONNECTICUT, INC. 2003-11-13 US disclosed
WO-2003089434-A2 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF CELLULAR GENOMICS, INC. (US) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212073-A1 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof PRKACA, MAP3K8, MAP3K1 EPHB4 4069/4885BTK 715/4885ABL1 82/4885
US-20050288295-A1 Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof MAP3K8, MAP3K1, PRKACA EPHB4 4328/4885BTK 477/4885ABL1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.